Extensive genomic analyses have revealed frequent inactivation of key tumor suppressors, such as neurofibromin 2 (NF2), BRCA1-associated protein 1 (BAP1), and cyclin-dependent kinase inhibitor 2A (CDKN2A), through various mechanisms, thereby providing new targets for treatment [7]. This evidence concerns the gene CDKN2A and neoplasm.